Inactive Instrument

Ventrus Biosciences Inc Stock price Nasdaq

Equities

US9228221019

Pharmaceuticals

End-of-day quote Nasdaq
- USD 0.00% Intraday chart for Ventrus Biosciences Inc
Sales 2023 * - Sales 2024 * - Capitalization 72.92M
Net income 2023 * -66M Net income 2024 * -81M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.93 x
P/E ratio 2024 *
-0.9 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 67.01%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 48 20-03-29
Chief Tech/Sci/R&D Officer - Nov. 07
Chief Tech/Sci/R&D Officer 52 20-05-31
Members of the board TitleAgeSince
Director/Board Member 60 17-12-13
Director/Board Member 52 20-10-19
Chairman 78 14-06-30
More insiders
Assembly Biosciences, Inc. is a clinical-stage biotechnology company engaged in the development of small molecule antiviral therapeutics. Its hepatitis B virus (HBV) pipeline includes potent, HBV core inhibitors in clinical development, which are designed to disrupt the virus replication cycle at several key points with a focus on achieving finite treatment and functional cures. Its HBV and hepatitis delta virus (HDV) pipeline also includes two complementary approaches: a viral entry inhibitor and an oral, liver-focused, interferon-alpha receptor agonist, with potential application for both HBV and as chronic suppressive therapy for HDV, which is associated with increased disease burden for HBV/HDV patients. The herpesvirus pipeline addresses two serious consequences associated with herpesvirus infections, high-recurrence genital herpes and transplant-associated herpesviruses. Its HBV and HDV programs include ABI-4334 (4334), ABI-5366 (5366), HBV/HDV inhibitor program, and others.
More about the company
  1. Stock
  2. Equities
  3. Stock Assembly Biosciences, Inc.
  4. Stock Ventrus Biosciences Inc - Nasdaq